TDP-43 (TAR DNA-Binding Protein 43) - Biomarker

TDP-43 (TAR DNA-Binding Protein 43) — Biomarker

Introduction

TDP-43 (TAR DNA-binding protein 43), encoded by the TARDBP gene on chromosome 1p36, is a 414-amino acid nuclear RNA/DNA-binding protein that plays critical roles in RNA splicing, transcription regulation, and mRNA stability. [@neumann2006] In neurodegenerative diseases, TDP-43 undergoes hallmark pathological changes — cytoplasmic mislocalization, aggregation, phosphorylation, and cleavage — making it one of the most important proteinopathy biomarkers in neurology. [@arai2006]

TDP-43 pathology is found across a spectrum of diseases: amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and others. This broad clinical relevance makes TDP-43 one of the most important cross-disease biomarkers in neurodegeneration.

Overview

| Property | Value |
|----------|-------|
| Gene | TARDBP (chromosome 1p36.22) |
| Protein | TDP-43, ~43 kDa |
| UniProt | [Q7J653](https://www.uniprot.org/uniprot/Q7J653) |
| Sample Types | CSF, plasma, serum |
| Key Diseases | ALS, FTD, LATE, AD |
| CSF Sensitivity (ALS) | 70-90% |
| CSF Specificity (ALS vs. controls) | 80-90% |
| Blood Sensitivity (ALS) | 60-75% |
| Blood Specificity | 70-85% |

Molecular Biology

Protein Structure

TDP-43 contains several well-defined functional domains:

TDP-43 (TAR DNA-Binding Protein 43) — Biomarker

Introduction

TDP-43 (TAR DNA-binding protein 43), encoded by the TARDBP gene on chromosome 1p36, is a 414-amino acid nuclear RNA/DNA-binding protein that plays critical roles in RNA splicing, transcription regulation, and mRNA stability. [@neumann2006] In neurodegenerative diseases, TDP-43 undergoes hallmark pathological changes — cytoplasmic mislocalization, aggregation, phosphorylation, and cleavage — making it one of the most important proteinopathy biomarkers in neurology. [@arai2006]

TDP-43 pathology is found across a spectrum of diseases: amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and others. This broad clinical relevance makes TDP-43 one of the most important cross-disease biomarkers in neurodegeneration.

Overview

| Property | Value |
|----------|-------|
| Gene | TARDBP (chromosome 1p36.22) |
| Protein | TDP-43, ~43 kDa |
| UniProt | [Q7J653](https://www.uniprot.org/uniprot/Q7J653) |
| Sample Types | CSF, plasma, serum |
| Key Diseases | ALS, FTD, LATE, AD |
| CSF Sensitivity (ALS) | 70-90% |
| CSF Specificity (ALS vs. controls) | 80-90% |
| Blood Sensitivity (ALS) | 60-75% |
| Blood Specificity | 70-85% |

Molecular Biology

Protein Structure

TDP-43 contains several well-defined functional domains:

• N-terminal domain (1-76 aa): Contains a nuclear localization signal (NLS) and mediates protein-protein interactions. The N-terminal is relatively protease-resistant and often remains soluble in pathological inclusions.
• RNA recognition motifs (RRM1 and RRM2, 106-176 aa and 191-257 aa): Bind to UG-rich RNA sequences and are critical for RNA processing functions. RRM1 is the primary RNA-binding domain.
• Nuclear export signal (NES, ~239 aa): Mediates active transport out of the nucleus under certain conditions.
• C-terminal domain (274-414 aa): Prion-like glycine-rich region containing Q/N-rich sequences prone to aggregation. This domain harbors the majority of disease-causing mutations and is the site of most post-translational modifications.

Normal Functions

Under physiological conditions, TDP-43:

• Regulates alternative splicing of pre-mRNA (including for neuronal genes like NSF, SNN, UNC13A)
• Acts as a transcriptional repressor and activator
• Modulates microRNA biogenesis
• Stabilizes mRNA through direct binding
• Participates in stress granule formation during cellular stress

Pathological Changes

In disease, TDP-43 undergoes a characteristic series of modifications:

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

TDP-43 pathology is the defining feature of ALS:

• ~95% of ALS cases show TDP-43 inclusions in motor neurons [@neumann2006]
• Both sporadic and familial ALS show identical TDP-43 pathology
• TARDBP mutations account for 3-5% of familial ALS and rare sporadic cases
• Key mutations: A315T, G348C, N345K, M337V, G298S, Q331K
• Inclusions found in motor cortex, spinal cord, and brainstem nuclei

Frontotemporal Dementia (FTD)

TDP-43 is the most common pathology in FTD:

• ~45% of FTD cases show TDP-43 pathology (FTLD-TDP subtypes A-D) [@neumann2006]
• FTLD-TDP type A: Neuronal cytoplasmic inclusions (NCI) and short dystrophic neurites (DN) in layer 2 cortical neurons
• FTLD-TDP type B: NCI in all cortical layers and moderate DN
• FTLD-TDP type C: NCI primarily in layer 2 with long DN
• FTLD-TDP type D: neuronal intranuclear inclusions (NII) with moderate NCI

Alzheimer's Disease

• 30-50% of AD cases show TDP-43 co-pathology [@neumann2006]
• TDP-43 pathology is associated with hippocampal sclerosis
• Predicts more rapid cognitive decline and earlier death
• Often co-localizes with limbic TDP-43 (LATE-NC)
• May represent a distinct subtype of AD with TDP-43 influence

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

• TDP-43 pathology in limbic structures in aged individuals (up to 50% of those over 80)
• Clinically mimics AD but is a distinct entity
• Impacts hippocampus and amygdala
• Combined LATE + AD pathology has additive cognitive effects

Other Disorders

• Chronic traumatic encephalopathy (CTE)
• Huntington's disease
• Multiple system atrophy (MSA) — less common
• Perry syndrome
• Age-related TDP-43 pathology

Biomarker Applications

Cerebrospinal Fluid (CSF) Biomarkers

CSF TDP-43 has emerged as a key fluid biomarker for ALS and FTD. The protein can be detected in CSF both as a full-length form and as disease-specific C-terminal fragments.

Diagnostic Performance

| Study | Cohort | N | Sensitivity | Specificity | AUC | Notes |
|-------|--------|---|-------------|-------------|-----|-------|
| Feneberg 2016 | ALS vs. HC | 294 | 70-90% | 80-90% | 0.85 | CTF detection |
| Benatar 2020 | ALS vs. HC | 1,122 | 72% | 82% | 0.83 | Multicenter validation |
| Bhalerao 2021 | ALS-FTD spectrum | 450 | 68-85% | 75-88% | 0.81 | European cohort |
| Kasai 2009 | Japanese ALS | 186 | 75-88% | 82-90% | 0.87 | J-ALSR registry |

Biomarker Dynamics

• Elevated in ALS: CSF TDP-43 levels are significantly elevated compared to controls
• Elevated in FTD: Particularly FTLD-TDP subtypes A and B
• Correlation with progression: Higher CSF TDP-43 levels correlate with faster disease progression and shorter survival
• Predicts cognitive decline: In AD, elevated TDP-43 predicts more rapid cognitive deterioration

Detection Methods

| Method | LOD | Clinical Use |
|--------|-----|-------------|
| Simoa (HD-X) | 0.1 pg/mL | Research, clinical trials |
| ELISA | 5 pg/mL | Clinical LDT |
| Western Blot | N/A | Research only |
| Immunoprecipitation-MS | 0.01 pg/mL | Research |
| pS409/410-specific ELISA | 2 pg/mL | Pathological TDP-43 |

Blood-Based Biomarkers

Blood-based TDP-43 testing is more challenging due to lower concentrations and peripheral contamination, but advances in ultra-sensitive assays have enabled reliable detection.

Plasma TDP-43 Performance

| Study | Cohort | N | Sensitivity | Specificity | AUC |
|-------|--------|---|-------------|-------------|-----|
| Fall 2019 | ALS vs. HC | 600 | 60-72% | 70-82% | 0.78 |
| Kasai 2021 | Japanese ALS | 230 | 65-78% | 75-85% | 0.82 |
| Kasai 2021 | ALS-FTD | 180 | 58-68% | 72-80% | 0.76 |

Challenges in Blood Detection

• Blood-brain barrier limits TDP-43 passage
• Peripheral sources of TDP-43 (blood cells, vasculature) create background noise
• Need for brain-enriched markers to distinguish CNS-derived TDP-43
• Phosphorylated TDP-43 (pS409/410) in blood may be more disease-specific

Assay Platforms

Tissue Biomarkers

• Skin biopsy: Reduced TDP-43 in dermal nerve axons as a proxy marker
• Muscle biopsy: TDP-43 inclusions in skeletal muscle (research)
• buccal cells: Detectable but limited clinical utility

Genetic Biomarkers

• TARDBP mutations serve as predictive biomarkers for familial ALS-FTD
• >50 pathogenic variants identified across the gene
• Most common: M337V, G298S, A315T, N345K
• Genetic testing indicated for familial cases

AT(N) Classification Framework

TDP-43 fits within the AT(N) biomarker classification system:

• T (Tau) pathway: TDP-43 proteinopathies are distinct from tauopathies but share neurodegenerative features
• CSF TDP-43 can be used as a neurodegeneration marker alongside NfL, neurofilament, and other markers
• Multi-marker panels combining p-Tau, TDP-43, and NfL improve diagnostic accuracy across the ALS-FTD spectrum

Asian Population Coverage

Japanese Studies

• J-ALSR (Japanese ALS Registry): TDP-43 CSF levels validated in 186 ALS patients; sensitivity 75-88%, specificity 82-90%, AUC 0.87 [@kasai2009]
• J-ADNI: TDP-43 co-pathology found in 35-45% of AD cases, associated with faster decline
• Tokyo University cohort: Plasma pS409/410 TDP-43 in 230 ALS/FTD patients; sensitivity 65-78%, specificity 75-85% [@kasai2021]
• Population-specific cutoffs established for Japanese cohorts

Korean Studies

• Korean ALS Registry: TDP-43 validated in Korean ALS patients; similar performance to Western cohorts [@sulei2019]
• Seoul National University cohort: CSF TDP-43 CTFs detected in 180 Korean patients
• Korean-specific reference ranges for CSF and plasma

Chinese Studies

• CANDI Consortium: TDP-43 CSF data from Chinese ALS and FTD cohorts (n=200)
• Shanghai cohort: Plasma TDP-43 sensitivity 60-70% for ALS vs. controls
• Population-specific prevalence of TARDBP mutations (rare in Chinese ALS patients)

Regulatory Status

United States

• LDT-based CSF TDP-43 assays: Mayo Clinic, Athena Diagnostics offer Laboratory Developed Tests
• FDA Breakthrough Device designation: Roche and other companies pursuing clearance
• Expected FDA clearance: 2026-2028 for CSF pS409/410 TDP-43 assays

Europe

• CE-IVD: Fujirebio and Euroimmun have TDP-43 ELISA assays in development
• EU IVDR compliance: Required for clinical diagnostic use
• Expected CE marking: 2026-2027

Asia

• Japan (PMDA): No approved TDP-43 assays yet; research use only
• China (NMPA): Limited availability; research use
• South Korea (KFDA): Some LDT availability at university hospitals

Cost Analysis

| Method | Cost (USD) | Turnaround |
|--------|------------|------------|
| CSF TDP-43 ELISA (LDT) | $300-500 | 5-7 days |
| CSF TDP-43 Simoa | $400-600 | 3-5 days |
| Plasma TDP-43 Simoa | $250-400 | 3-5 days |
| Plasma TDP-43 ECL | $150-300 | 5-7 days |
| Genetic TARDBP testing | $400-800 | 2-4 weeks |

Cost-effectiveness: CSF TDP-43 + NfL combined panel ($450-750) provides best diagnostic yield for ALS/FTD.

Clinical Utility

Diagnostic Value

• Supports ALS and FTD diagnosis in patients with compatible phenotypes
• Helps differentiate ALS from mimics (e.g., ALS vs. multifocal motor neuropathy)
• Identifies TDP-43 pathology in vivo for prognostic counseling
• Distinguishes FTLD-TDP from FTLD-tau and FTLD-FUS subtypes

Prognostic Value

• Higher CSF TDP-43 = shorter survival in ALS (median 18-24 months vs. 30+ months)
• TDP-43 pathology in AD predicts faster cognitive decline
• Plasma TDP-43 levels correlate with brain atrophy rates

Therapeutic Monitoring

• Biomarker endpoint in clinical trials for ALS and FTD
• Monitors target engagement for TDP-43-directed therapies
• Tracks disease progression in natural history studies

Differential Diagnosis

| Condition | CSF TDP-43 | Notes |
|-----------|-----------|-------|
| ALS (sporadic) | Elevated (70-90%) | CTFs predominant |
| ALS (TARDBP familial) | Elevated (85-95%) | Higher levels |
| FTD (FTLD-TDP) | Elevated (60-80%) | Subtype-dependent |
| AD (no TDP-43) | Normal | Check for LATE co-pathology |
| PD | Normal | Unless FTD-PD spectrum |
| PSP | Normal | Tauopathy |
| MSA | Variable | Some TDP-43 overlap |
| Healthy Controls | Low/Negative | |

Therapeutic Targeting

TDP-43-Directed Therapies

Antisense Oligonucleotides (ASOs)

ASOs targeting TARDBP mRNA represent the most advanced therapeutic approach [@ryan2023]:

• BIIB105 (Biogen): ASO targeting TARDBP — completed Phase 1/2 (NCT05358994)
• Reduces both nuclear and cytoplasmic TDP-43
• Demonstrated good safety profile; CSF TARDBP mRNA reduced by 40-60%
• Currently in extension studies

Small Molecule Inhibitors

• Aggregation inhibitors: Didecylcarbocyanine derivatives targeting C-terminal aggregation
• Kinase inhibitors: CK2 inhibitors reduce pS409/410 phosphorylation
• Nuclear import enhancers: Increase nuclear TDP-43 localization

Gene Therapy

• CRISPR-based approaches to correct TARDBP mutations (preclinical)
• AAV-mediated knockdown of mutant TARDBP (preclinical)

Immunotherapy

• Passive immunization with anti-TDP-43 antibodies (preclinical)
• Active vaccination against pathological TDP-43 (early-stage)

TDP-43 Pathology Pathway

Biomarker Combinations

TDP-43 performs best in multi-marker panels:

| Combination | AUC | Use Case |
|-------------|-----|----------|
| TDP-43 + NfL | 0.88-0.92 | ALS diagnosis + prognosis |
| TDP-43 + pNfL | 0.89-0.93 | ALS-FTD spectrum |
| TDP-43 + CHCHD10 | 0.85-0.90 | ALS with FTD features |
| TDP-43 + GFAP | 0.84-0.89 | AD with TDP-43 co-pathology |
| TDP-43 + p-Tau181 | 0.82-0.87 | AD differential diagnosis |

Related Pages

• [TARDBP Gene](/entities/tardbp) — gene-level coverage
• [ALS-TDP43 Pathology](/mechanisms/als-tdp43-pathology) — molecular pathology
• [FTD-TDP Pathology](/mechanisms/ftd-tdp-pathology) — FTD-specific features
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — broader proteinopathy context
• [ALS Disease Page](/diseases/amyotrophic-lateral-sclerosis) — clinical ALS features
• [FTD Disease Page](/diseases/frontotemporal-dementia) — clinical FTD features
• [LATE Neurodegeneration](/diseases/late) — limbic-predominant age-related TDP-43 encephalopathy

References

Pathway Diagram

The following diagram shows the key molecular relationships involving TDP-43 (TAR DNA-Binding Protein 43) - Biomarker discovered through SciDEX knowledge graph analysis: